Tempus AI reported its financial results for the fourth quarter and full year ended December 31, 2024. For Q4 2024, revenue reached $200.68 million, representing a 35.8% year-over-year growth. Full year 2024 revenue totaled $693.398 million, an increase of 30.4% over the previous year.
The company reported a net loss of $(13.014 million) for Q4 2024 and a full-year net loss of $(705.809 million). Adjusted EBITDA for Q4 2024 was $(7.752 million), and for the full year 2024, it was $(104.707 million).
Looking ahead, Tempus now expects full-year 2025 revenue of approximately $1.24 billion for the consolidated Tempus and Ambry Genetics business, representing approximately 79% annual growth. Crucially, the company projects to achieve adjusted EBITDA positive status for the full year 2025, targeting around $5 million, an improvement of approximately $110 million over 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.